Immunotherapy offers hope for young women with rare, Chemo-Resistant cancer
NCT ID NCT03135769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called avelumab in 24 women with a rare pregnancy-related cancer (GTN) that did not respond to standard chemotherapy. The goal was to see if the drug could lower tumor markers (hCG) to normal levels and allow treatment to stop. Avelumab works by helping the immune system attack the cancer cells, offering a potentially less toxic option for these young patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GESTATIONAL TROPHOBLASTIC NEOPLASIAS (GTN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aphp Hopital Tenon
Paris, 75020, France
-
Centre Francois Baclesse
Caen, 14000, France
-
Hospices Civils de Lyon - CHLS
Pierre-Bénite, 69495, France
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut Paoli-Calmettes
Marseille, 13000, France
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31000, France